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Background: Erectile dysfunction (ED) is a common condition in patients with type 1 or type 2 diabetes mellitus. The prevalence 
and predictors in our patient population are unknown since minimal data exist for this condition in South Africa.
Method: An observational, cross-sectional study was performed on 150 consecutive male patients aged ≥ 50 years, with either 
type 1 or type 2 diabetes mellitus, attending the Steve Biko Academic Hospital Diabetes Clinic. These patients were evaluated 
for diabetes mellitus control and medical complications, and for the presence of ED. Morning serum testosterone levels were 
determined.
Results: Some degree of ED was reported in 95% of the patients, with 51% reporting serious dysfunction. Using multivariate 
logistic regression, it was determined that the significant factors associated with ED were age, body mass index, the peripheral 
neuropathy score and diuretic therapy. Differences in quality-of-life scores were seen in some ED subgroups.
Conclusion: This study confirms the high prevalence of ED in diabetic male patients in a tertiary setting. It is suggested that 
universal screening should be performed for this population group. Multiple predictors of ED were identified in this study. ED 
negatively affected quality of life, but not in a statistically significant way.
Keywords: cardiovascular disease, diabetes mellitus, diuretic therapy, erectile dysfunction, glycaemic control, peripheral 
neuropathy
Introduction
Erectile dysfunction (ED) is a common problem in men with type 
1 or type 2 diabetes mellitus, but it is often missed by treating 
physicians.1–3 It occurs at a younger age and with greater 
frequency in men with diabetes mellitus compared to non-
diabetic men.1–3 The prevalence of erectile dysfunction in the 
general adult population in the USA was found to be between 
18% and 31%, with up to 78% of men ≥ 75 years being affected.4,5
A prevalence of 35% ED was found in a study as early as 1980 in 
patients with diabetes mellitus.1 The prevalence of ED was found 
to be 49% in men aged 40–88 years in a Canadian study,6 while 
severe ED was found in 30% of men in a large study in Israel.7 A 
prevalence of ED of as high as 71% was also demonstrated in 
another study in France.3
In South Africa, minimal data exist in this regard. De Klerk et al. 
reported a prevalence of 77% of ED in users of primary care in a 
black and mixed race urban population in the Western Cape.8 
Diabetes mellitus was one of the significant associated diseases, 
with a crude odds ratio of 3.35 (p 0.001). Webb and Rheeder found 
some degree of ED in 88% of men with type 1 or type 2 diabetes 
mellitus screened for complications at primary healthcare clinics 
in Tshwane.9 Thirty-six per cent of these patients had severe ED.9
Multiple modifiable risk factors were found to be independently 
associated with ED in several trials, including diabetes mellitus, 
obesity, current smoking and hypertension.5,6 The prevalence of 
ED increased progressively with age. Other important 
associations were treatment with insulin or oral hypoglycaemic 
agents, retinopathy, and symptomatic autonomic and peripheral 
neuropathy.1 The duration of diabetes mellitus, the presence of 
ischaemic heart disease, nephropathy and poor glycaemic 
control may also be associated with ED.1
Men with ED are also more likely to have hypertension and 
diabetes mellitus, or to have undiagnosed hyperglycaemia.6,10 ED 
severity seems to increase with age, diabetes mellitus duration, 
poor glycaemic control, the presence of microvascular 
complications, diuretic therapy and cardiovascular disease.7 The 
consumption of small amounts of alcohol and physical activity 
might be protective.
ED is often related to organic causes, such as vasculogenic and 
neurological abnormalities.3,11 The medical therapy on which 
these patients are placed can also contribute to ED.7 An underlying 
cause is often found after extensive evaluation in patients with 
ED, including conditions such as hypogonadism.12–14 Owing to 
insufficient evidence, it is unclear whether routine hormonal 
blood tests, such as the determination of serum testosterone 
levels, should be undertaken in all patients with ED.15,16
ED and atherosclerosis share similar risk factors, such as smoking, 
diabetes mellitus, dyslipidaemia, hypertension and obesity. 
There seems to be a strong link between ED and atherosclerotic 
vascular disease.6,10,17,18 Endothelial dysfunction is the common 
underlying factor linking ED with cardiovascular disease.19–21 This 
plays an important role in the development of atherosclerosis 
and systemic vascular diseases, such as diabetes mellitus, 
hypertension, dyslipidaemia, ischaemic heart disease, strokes 
and claudication.20
The symptoms of ED probably precede cardiovascular events.21,22 
ED can be an early marker for atherosclerosis, cardiovascular risk 
and subclinical vascular pathology.17,19,20,23 It can also be predictive 
of the presence and extent of subclinical atherosclerosis, 
independent of traditional risk factors.21 The overall ED prevalence 
in men with coronary artery disease seems to be high.17,22 ED 
prevalence in acute coronary syndrome was found to differ 
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according to the extent of coronary artery disease, with a higher 
prevalence in patients with worse atherosclerosis. Coronary 
atherosclerosis seems to be more severe in patients with ED.17,23 It 
has also been demonstrated in several prospective studies that ED 
can be predictive of coronary heart disease, cardiovascular events 
and death in patients with diabetes mellitus specifically.7,8,24
Since it has been suggested that ED might be an early symptom 
of generalised cardiovascular disease, patients should probably 
be systematically screened for ED as part of periodic examination 
programmes.23,25,26 This could lead to early detection and 
treatment of modifiable vascular risk factors, or existing vascular 
disease.22,25,26
Men with diabetes mellitus who develop ED experience a 
significant decline in quality of life, and an increase in depressive 
symptoms.2,27 Depression is also an important factor in the 
development of ED in patients with diabetes mellitus. The 
prognosis for ED in men with diabetes mellitus is poor. It was 
found that only 9% of these men regained erectile function over 
a five-year period in one prospective study. The development of 
ED was also significantly associated with poor glycaemic control 




This study was performed in an academic centre (Steve Biko 
Academic Hospital Diabetes Clinic, University of Pretoria).This is a 
tertiary diabetes mellitus clinic in a state hospital. The University 
of Pretoria Ethics Committee approved the study (213/2011).
Subject selection
One hundred and fifty consecutive convenience sampled male 
patients aged ≥ 50 years, with either type 1 or type 2 diabetes 
mellitus, were included. This study formed part of a larger study 
on late-onset hypogonadism, so men aged < 50 years were not 
included.
Research procedures
Information was obtained from the patients themselves, their 
hospital and clinic files, the hospital laboratory system, and from 
questionnaires which the patients completed.
Demographic variables, such as age, race, smoking history and 
employment status pertaining to the patients were recorded.
Clinical variables, including the type of diabetes mellitus, as well as 
the presence of hypertension and time since diagnosis, were 
recorded. A previous history of stroke, myocardial infarction, 
amputation, foot ulcerations, cataracts, revascularisation, 
nephropathy or retinopathy requiring laser therapy was obtained. 
Blood pressure was taken, body mass index (BMI) was calculated, 
and waist circumference (WC) measured. The medications used by 
patients at the time of the study were recorded.
The Sexual Health Inventory for Men (SHIM) questionnaire was 
completed by the patients.29 This is a basic five-point questionnaire 
on ED. Each answer is graded from 0 (no sexual activity or attempt at 
intercourse) to 5 (very good sexual function). The maximum score 
that patients could obtain was 25 and the minimum was 1. Based on 
the SHIM questionnaire, the patients were divided into groups: 
•  Severe ED (grade 4): 1–7.
•  Moderate ED (grade 3): 8–11.
•  Mild to moderate ED (grade 2): 12–16.
•  Mild ED (grade 1): 17–21.
•  No ED (grade 0): ≥ 22.
This questionnaire was completed by the study participants, with 
assistance from a trained medical professional, where needed.
A basic health-related, quality-of-life questionnaire, i.e the 
EuroQol (EQ-5D) health questionnaire, was completed by the 
patients.30 This questionnaire evaluates five different aspects, 
namely mobility, self-care, usual activities, pain and discomfort, 
and anxiety and depression. Patients scored 0 if they had no 
impairment, 1 if they had moderate problems, and 2 if they had 
severe impairment, adding up to a maximum of 10 points.
The World Health Organisation Rose angina questionnaire was 
used to diagnose intermittent claudication.31 It consists of nine 
questions, and based on the patients’ choice (out of two possible 
answers), intermittent claudication was either diagnosed or ruled 
out. A peripheral neuropathy questionnaire, i.e the modified 
Neuropathy Symptom Score, was also completed.32 This 
questionnaire contains five questions on the symptoms of 
peripheral neuropathy. Patients could answer “no” or “yes”, and 
grade the peripheral neuropathy by answering “worse at night”.
All four questionnaires were chosen for their simplicity and 
brevity. Although none of them were validated in a South African 
population, they have been used and validated in other 
international institutions.
Laboratory measurements
Biochemical variables included routine tests, such as a serum 
creatinine, serum low-density lipoprotein (LDL) cholesterol and the 
haemoglobin A1c (HbA1c) value. After the exclusion of a possible 
urinary tract infection with a spot urine dipstick, a spot urine 
specimen was collected to measure the albumin to creatinine ratio. 
Total testosterone was the only non-routine test that was performed.
Fasting blood tests were carried out between 7h00 and 10h00 
and were immediately refrigerated. They were transported to the 
Dr WJH Vermaak laboratory for analysis on the same day. The 
laboratory-specific normal reference range at this laboratory for 
total testosterone in males aged ≥ 50 years is 9.9–27.8 nmol/l.
Data analysis
Data were analysed with Stata® 12.33 Exposure between cases and 
non-cases was compared using appropriate tests for continuous 
and categorical data. Logistic regression was utilised to determine 
predictors of outcome with tests of calibration and validation, as 
required. To determine which variables to use in the multivariate 
model, univariate logistic regression was performed to evaluate 
the relationship between demographic, clinical and biochemical 
variables, and the different health-related questionnaires.
Variables with a p-value < 0.250 were entered into a multivariate 
model, with manual backward elimination based on the p-values 
in the model. Non-significant variables were dropped based on 
the p-value. Sensitivity, specificity, positive and negative 
predictive values were calculated. To determine the calibration of 
the final model, receiver operating characteristic (ROC) curve 
analysis was performed with calculation of the c-statistic. Tenfold 
cross-validation of the area under the ROC curve was used for 
validation.
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Table 1: The baseline characteristics of the study patients (clinical and biochemical variables)
Note: HbA1c: haemoglobin A1c, HDL: high-density lipoprotein, IQR: interquartile range, LDL: low-density lipoprotein, SD: standard deviation, TGs: triglycerides
*:Cardiovascular disease defined as any of the following: previous myocardial infarction; typical angina; ECG evidence of past myocardial infarction; angiographic or MIBI or stress ECG 
evidence of ischaemic heart disease                                        
**:SD = Standard deviation                                                                                        
***:IQR = Interquartile range
Variable n (%) Mean (SD)** Median (IQR)***
Type of diabetes mellitus
Type 1 13 (8.7)






Co-morbidities and medical complications
Hypertension 142 (94.7)
Past or present cardiovascular disease* 61 (40.7)
Proliferative diabetic retinopathy 38 (25.3)
Peripheral neuropathy 64 (43.2)
Intermittent claudication 10 (6.7)




Diabetes mellitus duration (years) 15 (8.7)
Hypertension 142 (94.7)
Hypertension duration (years) 12 (7–22)
Systolic blood pressure (mmHg) 134 (15.5)
Diastolic blood pressure (mmHg) 77 (9.3)
Current smoker 24 (16.0)
Past smoker 42 (28.0)
Body mass index (kg/m2) 30.7 (5.37)
Waist circumference (cm) 112 (16.4)
Medications
On insulin 127 (84.7)
On metformin 96 (64.0)
On statin 140 (93.3)
On diuretics 123 (82.0)
On fibrates 22 (14.7)
On beta blockers 68 (45.3)
Laboratory tests
Serum creatinine (μmol/l) 96 (79–133)
HbA1c (%) 7.9 (6.8–9.3)
Serum total testosterone (nmol/l) 9.88 (7.04–14.13)
Low total testosterone (nmol/l) 75 (50.0)
Total cholesterol (mmol/l)  4.09 (0.97)
TGs (mmol/l) 1.90 (1.20–2.50)
HDL (mmol/l) 0.99 (0.32)
LDL (mmol/l) 2.33 (0.70)
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Table 2: The prevalence of erectile dysfunction
*:According to the Sexual Health Inventory for Men questionnaire, a total score of 
22–25 meant no erectile dysfunction (grade 0); 17–21, mild erectile dysfunction 
(grade 1); 12–16, mild to moderate erectile dysfunction (grade 2); 8–11, moderate 
erectile dysfunction (grade 3); and 1–7, severe erectile dysfunction (grade 4)
Erectile dysfunction (grades)* n (%)
Grade 0 7 (4.7)
Grade 1 17 (11.3)
Grade 2 28 (18.7)
Grade 3 21 (14.0)
Grade 4 77 (51.3)
Total 150 (100.0)
Table 3: Total testosterone in the different erectile dysfunction categories
*:Normal total testosterone: 9.9–27.8 nmol/l
**:Low total testosterone: < 9.9 nmol/l
Erectile dysfunction Normal total testosterone* Low total testosterone** Total (%)
n (%) n (%) n (%)
Grade 0 3 (42.7) 4 (57.1) 7 (100.0)
Grade 1 11 (64.7) 6 (35.3) 17 (100.0)
Grade 2 10 (35.7) 18 (64.3) 28 (100.0)
Grade 3 12 (57.1) 9 (42.9) 21 (100.0)
Grade 4 39 (50.7) 38 (49.4) 77 (100.0)
Total 75 (50.0) 75 (50.0) 150 (100.0)
Table 4: Summary of univariate analysis of multiple statistically significant variables with erectile dysfunction (grade 0–2 versus grade 3–4 erectile 
dysfunction)
Note: ED: erectile dysfunction, IQR: interquartile range, SD: standard deviation
Variable ED grades 0–2 ED grades 3–4 p-value
Age [mean (SD)] 59 (6.6) 64 (8.0) < 0.001
Race
White, n (%) 21 (40.4) 58 (59.2)
Black, n (%) 16 (30.8) 29 (29.6)
Coloured, n (%) 8 (15.4) 7 (7.1) 0.033
Asian, n (%) 7 (13.5) 4 (4.1)
Smoker 
Never, n (%) 30 (57.7) 54 (55.1)
Current, n (%) 13 (25) 11 (11.2) 0.026
Past, n (%) 9 (17.3) 33(33.7)
Systolic blood pressure [mean (SD)] 130 (14.7) 136 (15.6) 0.034
Body mass index [mean (SD)] 29 (5.0) 31.6 (5.4) 0.006
Waist circumference [mean (SD)] 108 (15.7) 115 (16.4) 0.021
Serum creatinine [median (IQR)] 85 (76–106) 99 (83–146) 0.008
Peripheral neuropathy score [mean (SD)] 1.9 (2.2) 3.3 (3.0) 0.005
On a diuretic, n (%) 33 (63.5) 90 (91.8) < 0.001
Table 5: Multivariate associations for erectile dysfunction (grades 0–2 versus grades 3–4)
Note: CI: confidence interval, OR: odds ratio, SE: standard error
Associations OR SE 95% CI (lower limit) 95% CI (upper limit) p-value
Age 1.11 0.03 1.05 1.17 < 0.001
Body mass index 1.09 0.05 1.00 1.18 0.050
Peripheral neuropathy score 1.22 0.10 1.04 1.45 0.018
On diuretics 5.26 2.75 1.89 14.68 0.002
Results
Ninety-one per cent of the patients had type 2 diabetes mellitus. 
The mean age was 62  years [standard deviation (SD) 7.9]. Just 
over half of the patients were white (53%) and 30% were black. 
The mean duration of diabetes mellitus was 15  years (SD 8.7). 
Ninety-five per cent of the patients were previously diagnosed 
with hypertension, but this was relatively well controlled, with a 
mean systolic blood pressure (SBP) of 134 mmHg (SD 15.5) and 
mean diastolic blood pressure of 77 mmHg (SD 9.3). The patients 
were obese, with a mean BMI of 30.7 kg/m2 (SD 5.4), and a mean 
WC of 112  cm (SD 16.4). Sixty-six per cent of the patients were 
current (24%) or past (42%) smokers.
The median serum creatinine was 96  μmol/l [interquartile range 
(IQR) 79–133]. The patients’ diabetes mellitus was better controlled 
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Age, BMI, the peripheral neuropathy score and diuretic therapy 
were significant multivariate associations of ED (grades 0–2 
versus grades 3–4) (Table 5).
The area under the ROC curve was 0.797 for this model in 
predicting ED. The sensitivity was 90%, the specificity was 55%, 
the positive predictive value was 80%, the negative predictive 
value was 73%, and 78% was correctly classified. Table 6 
summarises the the tenfold cross-validation of the area under the 
ROC curve.
Erectile dysfunction and quality of life
When ED was regrouped into three categories to ensure adequate 
numbers in each group, i.e. grades 0–1, grades 2–3, or grade 4, an 
association was demonstrated with quality of life, especially 
between the grades 0–1 and grade 4 ED groups. This test 
approached, but did not reach, statistical significance. (Table 7)
Although the EQ-5D has not been validated in a South African 
population, the Cronbach’s alpha  reliability coefficient internal 
consistency was 0.7610, which meant that it was acceptable to 
use in our setting.
Discussion
ED was found in 95% of this group of patients with type 1 and 
type 2 diabetes mellitus. Fifty-one per cent reported serious ED. 
The prevalence in our study was higher than that described in the 
literature.1,3,4,6–9 This may be because of patients’ advanced 
medical complications, co-morbid diseases and numerous drug 
therapies.34,35 There was also an exceptionally high number of 
current or ex-smokers (44%) in our patient population. The higher 
prevalence in this study could also be explained by the exclusion 
of younger patients with diabetes mellitus, compared to other 
studies.1–3
Univariate associations were age, race, smoking status, SBP, BMI, 
WC, serum creatinine, the peripheral neuropathy score and 
diuretic therapy. After multivariate logistic regression, remaining 
significant factors were age, BMI, the peripheral neuropathy score 
and diuretic therapy. Statistically significant associations with ED 
were not demonstrated with other drug classes, such as beta 
than expected, with a median HbA1c of 7.9% (IQR 6.8–9.3). The mean 
LDL was above target at 2.33  mmol/l (SD 0.7). The median 
triglycerides was 1.90  mmol/l (IQR 1.20–2.50). The median serum 
total testosterone was 9.88 nmol/l (IQR 7.04–14.13).
The baseline characteristics of patients’ therapy and their diabetic 
complications are shown in Table 1. Forty-one per cent of patients 
were known to have cardiovascular disease, and less than 7% had 
intermittent claudication, as defined by the Rose questionnaire. 
Microvascular complications were common. Symptoms of 
significant peripheral neuropathy were present in 43% of the study 
population, microalbuminuria in 48% of patients, and proliferative 
diabetic retinopathy in 25%. Fifty-nine per cent of the study 
participants had cataracts at some point.
Eighty-five per cent of the patients had to be managed on insulin 
therapy. Metformin was prescribed to 64% of them. Statin usage 
was high at 93%, but fibrate use was low at 15%. Diuretics were 
prescribed to 82% of the study population, and 45% of the 
patients were on beta blockers.
The prevalence of erectile dysfunction
The prevalence of ED is shown in Table 2. Less than 5% of patients 
had no ED (grade 0), and 51% of patients had severe ED (grade 4). 
Forty-four per cent had milder degrees of ED.
Total testosterone levels in patients with erectile 
dysfunction
The distribution of low and normal total testosterone in the 
different ED categories is demonstrated in Table 3. The Fisher’s 
exact result of 0.369 was non-significant (p > 0.05), which implied 
that there was no association in this study between the two 
variables of total testosterone and ED.
Associations of erectile dysfunction
The statistically significant univariate associations of ED are 
summarised in Table 4. These variables were age, race, smoking status, 
SBP, BMI, WC, serum creatinine, the peripheral neuropathy score and 
diuretic usage. To simplify the statistical analysis, and because of the 
low numbers in some of the ED categories, ED was regrouped into two 
groups, i.e grades 0–2 and grades 3– 4, and then compared.
Table 6: Summary of the tenfold cross-validation of the area under the receiver operating characteristic curve
Note: CI: confidence interval, ED: erectile dysfunction, ROC: receiver operating characteristic SE: standard error
Model Tenfold cross-validation ROC area SE 95% CI
Lower limit Upper limit
ED Before 0.770 0.041 0.690 0.850
After 0.720 0.045 0.632 0.807
Table 7: Erectile dysfunction and quality-of-life score (EQ-5D]
Note: EQ-5D: EuroQol
*Kruskal-Wallis test: p < 0.0513
Erectile dysfunction category n Quality-of-life score
Median* Interquartile range
25th Percentile 75th Percentile
Grades 0–1 24 1 0 2
Grades 2–3 49 1 0 3
Grade 4 77 2 0 3
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Testosterone therapy may be useful for improving vasculogenic ED 
in men with low or low to normal testosterone levels, especially 
with serum testosterone levels below 12 nmol/l.36 It can moderately 
improve the number of nocturnal erections, sexual thoughts, 
number of occasions of successful intercourse and erectile function, 
but it has no effect on erectile function in eugonadal men.36 This 
effect tends to decline over time, and the risks and benefits, as well 
as long-term safety data, are not available, especially regarding 
prostatic disease and cardiovascular health.36,37
While effective therapies are not available in the South African 
public health sector, the prevention of ED is important. A period 
of intensive glycaemic therapy significantly reduced the 
prevalence of ED 10  years later in men with type 1 diabetes 
mellitus who had some target organ damage at baseline in the 
Diabetes Control and Complications Trial.38 The risk of ED was 
directly associated with mean HbA1c during the trial duration.
Conclusion
This study confirmed the high prevalence of ED in a tertiary diabetic 
clinic setting, and that it may negatively affect quality of life. The high 
prevalence of ED should prompt all male patients aged ≥ 50 years 
with diabetes mellitus to be screened at tertiary clinics for this 
condition. Moreover, the clear association that is well described in 
the literature between ED and cardiovascular disease should prompt 
the screening of patients with ED for ischaemic heart disease.
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